Press-release for stocks publishing date 2023 - 01

Prices are updated after-hours

publishing date : 2023 - 01 - 09 source : Www.biospace.com

save search

Relmada Therapeutics Appoints CNS Therapeutic Expert Cedric O'Gorman MD as Chief Medical Officer
Published: 2023-01-09 (Crawled : 01:00) - biospace.com/
RLMD | $3.91 1.03% 1.02% 140K

Health Technology

| 18.84% | O: 2.74% H: 5.03% C: 0.3%
medical therapeutics

Quantum-Si Begins Commercial Shipments of the PlatinumTM Protein Sequencing System and Provides Business Updates at the 41st Annual J.P. Morgan Healthcare Conference
Published: 2023-01-09 (Crawled : 01:00) - biospace.com/
QSI | $1.7 4.94% 4.71% 630K

Professional, Scientific, and T...

| -1.16% | O: 2.91% H: 9.04% C: 5.65%
conference system commercial

Guardant Health Announces Preliminary Fourth Quarter and Full Year 2022 Results
Published: 2023-01-09 (Crawled : 01:00) - biospace.com/
GH | News 4 | $17.34 -1.42% -1.44% 1.8M

Health Services

| -33.18% | O: 7.9% H: 4.54% C: -0.75%
health year results

AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2022, Provides Financial Outlook for 2023
Published: 2023-01-09 (Crawled : 01:00) - biospace.com/
ATRC | $23.17 2.03% 1.86% 950K

Health Technology

| -49.32% | O: 0.66% H: 0.17% C: -4.61%
year financial

Establishment Labs Announces Preliminary Unaudited Revenue for Fourth Quarter and Fiscal Year 2022
Published: 2023-01-09 (Crawled : 01:00) - biospace.com/
ESTA | $49.69 2.94% 3.03% 270K

Health Technology

| -22.13% | O: 2.02% H: 0.0% C: -5.62%
year

Rigel Pharmaceuticals Provides Business Update - January 9, 2023
Published: 2023-01-09 (Crawled : 01:00) - biospace.com/
RIGL | $1.14 0.89% 0.44% 430K

Health Technology

| -8.8% | O: 4.8% H: 12.98% C: 7.63%
pharmaceuticals update

Instil Bio Announces Resumption of Clinical Trial of CoStAR-TIL Candidate ITIL-306 in Lung, Ovarian, and Renal Cancer
Published: 2023-01-09 (Crawled : 23:00) - biospace.com/
TIL | $10.75 0.37% -1.04% 1.8K

Professional, Scientific, and T...

| 1596.39% | O: 10.46% H: 6.01% C: -4.29%
itil-306 candidate renal trial cancer

Ocuphire Pharma Announces First Patient Enrolled in VEGA-2 Pivotal Phase 3 Trial of Nyxol® in Presbyopia
Published: 2023-01-09 (Crawled : 23:00) - biospace.com/
OCUP | News | $1.54 1.99% 1.31% 140K

Health Technology

| -51.42% | O: 1.89% H: 5.26% C: 5.26%
nyxol pharma trial presbyopia

Krystal Biotech Announces FDA’s 3-Month Extension of BLA PDUFA Date and Regulatory Update for B-VEC to Treat Patients with Dystrophic Epidermolysis BullosaNEW PDUFA DATE OF MAY 19, 2023
Published: 2023-01-09 (Crawled : 22:00) - biospace.com/
KRYS | News | $162.04 3.05% 3.04% 220K

Health Technology

| 95.56% | O: -5.18% H: 0.0% C: -6.05%
pdufa biotech extension update

atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917
Published: 2023-01-09 (Crawled : 22:00) - biospace.com/
ATAI | $1.97 5.35% 5.08% 1.1M

Manufacturing

| 8.24% | O: 1.65% H: 0.54% C: -10.81%
grx-917 sciences life trial therapeutics positive results phase 1

Trevena Enrolls First Subject in TRV045 Proof-of-Concept Trial Evaluating S1PR Mechanism of Action and Target Engagement
Published: 2023-01-09 (Crawled : 22:00) - biospace.com/
TRVN | $0.388 4.81% -2.27% 140K

Health Technology

| -78.09% | O: 0.0% H: 2.81% C: 0.0%
trv045 trial

IDEAYA Announces IND Clearance by U.S. FDA enabling Phase 1 Initiation for First-in-Class PARG Development Candidate IDE161
Published: 2023-01-09 (Crawled : 22:00) - biospace.com/
IDYA | News | $39.02 3.8% 3.68% 490K

Health Technology

| 125.94% | O: 0.0% H: 0.58% C: -3.07%
ide161 fda clearance candidate enabling phase 1

Tenaya Therapeutics Announces TN-201 IND Clearance and Anticipated 2023 Milestones
Published: 2023-01-09 (Crawled : 21:00) - biospace.com/
TNYA | $4.45 0.45% 0.45% 150K

| 127.04% | O: 12.24% H: 0.0% C: -9.55%
tn-201 clearance therapeutics

Biomea Fusion to Present at 41st Annual J.P. Morgan Healthcare Conference and Highlight 2023 Corporate Milestones
Published: 2023-01-09 (Crawled : 21:00) - biospace.com/
BMEA | $10.98 1.39% 1.28% 690K

Professional, Scientific, and T...

| 55.74% | O: -1.7% H: 4.47% C: -1.88%
conference

Solid Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
Published: 2023-01-09 (Crawled : 21:00) - biospace.com/
SLDB | $9.11 0.77% 0.44% 300K

Health Technology

| 55.73% | O: 2.56% H: 1.17% C: 0.0%
conference

Inspire Medical Systems, Inc. Announces Preliminary Results for the Fourth Quarter and Full Year 2022
Published: 2023-01-09 (Crawled : 21:00) - biospace.com/
INSP | $233.93 3.87% -1.68% 340K

Health Technology

| -5.13% | O: 3.11% H: 0.1% C: -4.42%
inspire medical year

Biofrontera Inc. Announces First Patient Dosed in Pivotal Phase 3 Clinical Study Evaluating Ameluz(R)-PDT for the Treatment of Actinic Keratosis on the Extremities, Neck and Trunk
Published: 2023-01-09 (Crawled : 21:00) - biospace.com/
BFRI | $1.495 3.46% 2.36% 54K

| -91.67% | O: 2.2% H: 21.73% C: 9.81%
treatment study

Algernon Pharmaceuticals Announces Plans for a 180 Patient Phase 2b Chronic Cough Study of Ifenprodil Ifenprodil Represents a Novel First-in-Class Potential Treatment for Chronic Cough
Published: 2023-01-09 (Crawled : 21:00) - biospace.com/
AGNPF | $0.089 24.3% 178.69% 75K

Health Technology

| -94.77% | O: -4.07% H: 0.0% C: 0.0%
treatment pharmaceuticals potential study phase 2b

Ocugen Announces Positive Top-Line Data for COVID-19 Vaccine Candidate COVAXIN™ (BBV152) in Phase 2/3 Immuno-bridging and Broadening Study: Both Co-primary Endpoints Met
Published: 2023-01-09 (Crawled : 21:00) - biospace.com/
OCGN | News A | $1.25 0.81% 0.0% 6.7M

Health Technology

| -7.69% | O: 18.46% H: 0.65% C: -18.83%
covid-19 candidate vaccine positive

Solid Biosciences Appoints Kevin Tan, CFA, as Chief Financial Officer
Published: 2023-01-09 (Crawled : 20:00) - biospace.com/
SLDB | $9.11 0.77% 0.44% 300K

Health Technology

| 55.73% | O: 2.56% H: 1.17% C: 0.0%
financial